- Home
- YMAT vs HOTH Comparison
YMAT vs HOTH Comparison
Compare YMAT & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YMAT | HOTH |
|---|---|---|
| Founded | 1970 | 2017 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4M | 16.6M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | YMAT | HOTH |
|---|---|---|
| Price | $0.56 | $1.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 105.3K | ★ 283.2K |
| Earning Date | 02-09-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,054,081.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.83 | ★ N/A |
| Revenue Growth | ★ 11.79 | N/A |
| 52 Week Low | $0.40 | $0.66 |
| 52 Week High | $6.45 | $2.12 |
Technical Indicators
Market Signals| Indicator | YMAT | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 44.66 |
| Support Level | N/A | $1.01 |
| Resistance Level | N/A | $1.12 |
| Average True Range (ATR) | 0.00 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 53.27 |
Price Performance
Historical ComparisonAbout YMAT J-Star Holding Co. Ltd. Ordinary Shares
J Star Holding Co Ltd is engaged in the research, development and manufacturing of carbon fiber for a wide variety of products including carbon bicycles, carbon rackets, automotive parts, outdoor sports gears, and healthcare products.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).